SpyGlass Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring between February 5, 2026, and February 9, 2026. The filing documents the completion of SpyGlass Pharma, Inc.'s initial public offering (IPO) and associated corporate governance changes. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "SGP."
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The only financial data provided relates to the IPO transaction and director compensation:
- IPO Proceeds: The company sold 10,781,250 shares of common stock, including 1,406,250 shares from the full exercise of the underwriters' option.
- Director Compensation: Non-employee directors receive a base annual retainer of $40,000, with additional retainers for committee service ranging from $5,000 to $30,000.
- Equity Grants: New director Habib Dable was granted an option to purchase 27,400 shares, vesting monthly over 36 months, with an annual refresh grant of 13,700 shares.
Material Changes
The primary material change is the transition from a private to a public company via the IPO closing on February 9, 2026. Specific changes include:
- Board Appointment: Habib Dable was appointed to the Board of Directors on February 5, 2026, serving as a Class I director and member of the compensation committee.
- Corporate Governance: The company filed an Amended and Restated Certificate of Incorporation and adopted Amended and Restated Bylaws effective February 9, 2026.
Outlook, Risks, and Management Commentary
Management has designated specific channels for material disclosures, including SEC filings, the company website, press releases, and social media. The filing references "Risk Factors" and "Description of Capital Stock" detailed in the Prospectus filed on February 6, 2026, but does not enumerate specific risks within this 8-K text. No forward-looking guidance regarding product development timelines or financial projections is included in this document.
Investor Verification Checklist
- Verify the final IPO share price and total capital raised in the Prospectus filed on February 6, 2026.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for specific governance provisions.
- Confirm the vesting schedule and exercise price of the stock options granted to Habib Dable in the 2026 Equity Incentive Plan.
- Examine the "Risk Factors" section of the Prospectus for details on clinical trial risks and liquidity constraints.